RiverVest Venture Partners has announced it has closed its fifth fund — RiverVest Venture Fund V — with $275 million of capital commitments.
RiverVest, based in St. Louis, Mo., is a venture capital firm that targets investments in early-stage … Continue Reading
OrbiMed has announced it has raised $3.5 billion in commitments for its latest private investment funds.
The investments are broken down as follows:
NovaQuest Private Equity has announced it has acquired CoreRx.
CoreRx, based in Clearwater, Fla., is a contract development and manufacturing organization that serves small to mid-sized pharmaceutical and biotech organizations. Founded in 2006, the company offers preformulation, formulation, analytical … Continue Reading
Frazier Healthcare Partners has acquired a 50% stake in CSafe Global from Thomas H. Lee Partners (THL), according to a news release.
CSafe Global, based in Dayton, Ohio, is a provider of cold chain shipping solutions to global … Continue Reading
Blackstone has announced the closing of its inaugural life sciences fund with $4.6 billion of total capital commitments.
The company stated that the fund, Blackstone Life Sciences V, is the largest life sciences private fund raised to date.
Blackstone Life … Continue Reading
Maravai LifeSciences, a portfolio company of GTCR, has announced it has acquired MockV Solutions.
Maravai, based in San Diego, is a provider of life science reagents and services to researchers and biotech partners. The company focuses on DNA and … Continue Reading
The Blackstone Group has announced the closing of its acquisition of Clarus. The business will now operate as Blackstone Life Sciences.
Blackstone indicated that its new private investment platform will invest across the lifecycle of companies and products within life … Continue Reading
Avista Capital Partners will acquire Miraca Life Sciences from Miraca Holdings, according to a news release.
Miraca Life Sciences, based in Irving, Texas, is a national, independent anatomic pathology lab providing subspecialty anatomic pathology services in the fields … Continue Reading
Signet Healthcare Partners has announced it has closed its fourth life science fund, Signet Healthcare Partners IV L.P., with $137.2 million of capital commitments.
Signet, based in New York and founded in 1998, is a private equity fund that … Continue Reading
Warburg Pincus has announced it will invest in Hygenia.
Warburg Pincus, headquartered in New York, is a PE firm that takes a long-term perspective and invest in businesses at all stages of development. It invests healthcare and several other … Continue Reading
Precision BioSciences has announced it has secured $25.6 million in series A financing.
Precision BioSciences is a Durham, N.C.-based genome editing company. Its ARCUS genome editing technology is designed to produce nucleases that can insert, remove and modify DNA in … Continue Reading
Andrew Alliance has announced the closing of a series B financing round.
Andrew Alliance, which is based in Switzerland and will be opening an office in Boston, is a developer of life science robotics. In January 2013, Andrew Alliance … Continue Reading
iRhythm Technologies has announced it completed raising $17 million in series E financing.
iRhythm, headquartered in San Francisco, is a privately held healthcare information services company that focuses on the management of cardiac arrhythmia information.
The financing round was … Continue Reading
Adaptive Biotechnologies has announced it has completed a series C financing round and completed a newly created series D round of financing with a $105 million investment from Viking Global Investors.
Adaptive Biotechnologies, based in Seattle, Wash., is an … Continue Reading
Clarus Ventures has set out to raise $375 million for a new life sciences VC fund, according to multiple reports, including a San Francisco Business Times report.
Clarus Ventures is a healthcare VC firm with offices in Cambridge, Mass., … Continue Reading
Akebia Therapeutics has announced (pdf) it has completed a $41 million Series C financing.
Akebia Therapeutics, headquartered in Cincinnati, is a biopharmaceutical company focused on the development of small molecules for the treatment of anemia and vascular disease.
Satter … Continue Reading
Radius Health, Inc., has announced it has completed a new equity financing of $43 million.
Radius, based in a Cambridge, Mass., is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health … Continue Reading
In light of the integrity and clinical issues raised by the New England Compounding Centers far-reaching recalls in late 2012, the FDA has urged officials from all 50 states to close regulatory loopholes involving the safety of compounding drugs for … Continue Reading
Versartis, Inc. has announced it has raised $25 million in series C financing led by Aisling Capital.
Versartis, headquartered in Redwood City, Calif., is a biotechnology company developing therapeutics for patients with endocrine disorders.
Aisling Capital, headquartered in … Continue Reading
Referencing S. O’Shea, R. Ricchio’s Law360 article “Mixing Agency Rules May Mean More Taxable Medical Devices" , our McGuireWoods colleagues Melissa Gilmore and Mary DeBartolo recently queried which medical devices are taxable and noted conflicting agency interpretations.
As our colleagues note, … Continue Reading
Just minutes and hours after the US Supreme Court issued its much-anticipated decision regarding the constitutionality of The Patient Protection and Affordable Care Act (PPACA or ACA) on June 28th, commentators in all walks of life scrambled to offer their insights … Continue Reading
Apparently some early participants in the accountable care organization (ACO) program are experiencing problems accessing crucial CMS (Centers for Medicare and Medicaid Services) data.
The acting administrator of CMS has reported to ACO supervisors and others at a conference last … Continue Reading
It is virtually impossible to turn on a TV, radio or podcast . . . or pick up a newspaper or peruse the internet . . . without hearing that the U.S. Supreme Court today began three days of potentially … Continue Reading
Perhaps despite not having the cache of ‘guaranteed-weight-loss’, ‘quit smoking now’ or even a cure-all for cancer, pharmaceuticals for the treatment of rare diseases can be an attractive investment strategy.
Amicus Therapeutics is the developer of small molecule, orally administered … Continue Reading